These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 983809)

  • 1. Problems encountered in long-term treatment with anticoagulants.
    Husted S; Andreasen F
    Acta Med Scand; 1976; 200(5):379-84. PubMed ID: 983809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of thromboembolic events after protocolized warfarin reversal with 3-factor PCC and factor VIIa.
    Barton CA; Johnson NB; Case J; Warden B; Hughes D; Zimmerman J; Roberti G; McMillian WD; Schreiber M
    Am J Emerg Med; 2015 Nov; 33(11):1562-6. PubMed ID: 26143317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk.
    Larson BJ; Zumberg MS; Kitchens CS
    Chest; 2005 Mar; 127(3):922-7. PubMed ID: 15764777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Warfarin therapy for atrial fibrillation in general practice--is bleeding risk underestimated?
    Bratland B; Hornnes MB
    Tidsskr Nor Laegeforen; 2014 Jan; 134(2):175-9. PubMed ID: 24477151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral anticoagulant therapies: balancing the risks.
    Nutescu EA
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S3-11. PubMed ID: 23640530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs.
    Penning-van Beest FJ; van Meegen E; Rosendaal FR; Stricker BH
    Clin Pharmacol Ther; 2001 Jun; 69(6):451-7. PubMed ID: 11406743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Warfarin-induced bleeding complications - clinical presentation and therapeutic options.
    Wiedermann CJ; Stockner I
    Thromb Res; 2008; 122 Suppl 2():S13-8. PubMed ID: 18549907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of bleeding with oral anticoagulants in patients with atrial fibrillation.
    Bosch J; Eikelboom JW
    Hamostaseologie; 2015; 35(4):351-7. PubMed ID: 26013362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulation therapy: bleeding and thromboembolic complications.
    Sweeney KG; Gray DP; Evans P; Steele R
    Lancet; 1996 Nov; 348(9039):1456-7. PubMed ID: 8937309
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessing hyperanticoagulation of dental patients undergoing warfarin therapy.
    Cripps K; Kerns DG; Greenwell H
    Mil Med; 1996 Nov; 161(11):679-82. PubMed ID: 8961723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [-Anticoagulant drugs-].
    Gulba DC
    Herz; 1996 Feb; 21(1):12-27. PubMed ID: 8647576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota.
    Gitter MJ; Jaeger TM; Petterson TM; Gersh BJ; Silverstein MD
    Mayo Clin Proc; 1995 Aug; 70(8):725-33. PubMed ID: 7630209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort.
    Maagdenberg H; Bierings MB; van Ommen CH; van der Meer FJM; Appel IM; Tamminga RYJ; de Boer A; Maitland-van der Zee AH
    J Thromb Haemost; 2018 Jan; 16(1):116-124. PubMed ID: 29108090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of drug-induced anticoagulation: old solutions and new problems.
    Dzik WS
    Transfusion; 2012 May; 52 Suppl 1():45S-55S. PubMed ID: 22578371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry.
    Königsbrügge O; Simon A; Domanovits H; Pabinger I; Ay C
    BMC Cardiovasc Disord; 2016 Dec; 16(1):254. PubMed ID: 27938343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulation patient self-monitoring in the United States: considerations for clinical practice adoption.
    Nutescu EA; Bathija S; Sharp LK; Gerber BS; Schumock GT; Fitzgibbon ML
    Pharmacotherapy; 2011 Dec; 31(12):1161-74. PubMed ID: 22122179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
    Fenger-Eriksen C; Münster AM; Grove EL
    Acta Anaesthesiol Scand; 2014 Jul; 58(6):651-9. PubMed ID: 24716468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.